Victorian Cancer Agency Cancer Health Services Research grants awarded
As part of the Victorian Government’s Victoria Cancer Action Plan 2016-2020, five of the state’s most brilliant scientific minds will receive $1.5 million in grants to support their ground-breaking discoveries and medical breakthroughs in cancer research. The grants,…
Expressions of interest for membership to TGA’s statutory advisory committees
The Therapeutic Goods Administration (TGA) is seeking expressions of interest (EOI) from professionals with expertise in relevant scientific and medical fields or appropriate consumer health issues to support our functions as a best practice regulator. As a committee…
Kesem Health selected for ANDHealth+ 2018
Kesem Health announced today it succeeded in securing a place in Australian’s only mid-stage digital health program, ANDHealth+. Kesem Health will receive up to $60,000 worth of specialist third-party services and up to $150,000 of in-kind support to…
Davies Collison Cave announces 20 promotions and expands it service offering with lateral hire of a new team.
New team and service offering Davies Collison Cave Law is pleased to announce that it has expanded its service offering into the corporate and private client advisory, mergers and acquisitions, tax and property areas with the appointment of…
2018 ATSE Clunies Ross Award Recepients
2018 ATSE Clunies Ross Entrepreneur of the Year: Dr Erol Harvey FTSE TRANSLATING MICRO AND NANO TECHNOLOGY Scientist, educator and entrepreneur Dr Erol Harvey has made outstanding contributions to Australia through the world-leading microfluidic engineering company MiniFAB, his…
Cynata Announces Research Collaboration with University of New South Wales to Develop Stem Cell Therapies for Coronary Artery Disease
Melbourne, Australia; 18 June 2018: Australian stem cell and regenerative medicine company Cynata Therapeutics Limited (ASX: CYP) is pleased to announce that it has commenced a preclinical research collaboration with UNSW Sydney (the University of New South Wales)…
Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases
Prana receives ethics committee approval for a clinical trial evaluating first in human dosing of PBT434 Recruitment has commenced for the first cohort of healthy volunteers Study conducted by leading Australian early phase clinical trial facility Nucleus Network,…
“Medicines Development for Global Health Secures U.S. FDA Approval For Moxidectin For The Treatment Of River Blindness”
MELBOURNE, GENEVA, and NEW YORK Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.) Food and Drug Administration (FDA) approved moxidectin 8…
Piper Alderman Melbourne has relocated
From 4 June 2018 you will find them at Level 23, 459 Collins Street, Melbourne, 3000 Commencing Monday 4 June 2018, the Melbourne office of Piper Alderman will operate from Level 23, 459 Collins Street, Melbourne. This change will see…
Member news: Success story of a patient on GrunBiotic’s Neurofolin
Member news: Success story of a patient on GrunBiotic’s Neurofolin: https://www.mamamia.com.au/folate-depression/”
AdAlta secures key manufacturing agreements for AD-214
AdAlta secures key manufacturing agreements for AD-214 Please click here for an ASX announcement relating to the execution of key manufacturing agreements for AD-214
Walter and Eliza Hall Institute news: Structure of protein pair provides blueprint for future drugs
Walter and Eliza Hall Institute researchers have visualised for the first time how the protein SOCS1 ‘switches off’ cell signalling to dampen immune responses and block cancer growth. The atomic-level structure of SOCS1 binding to its partner protein…
